Companies / Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

NasdaqCIK 1937993PONTE VEDRA, FL

Financials

Revenueโ€”
Net income$-13.24M
Total debt$829.7K
Cash$2.39M
Diluted EPS$-6.64
Shares outstanding2.9M

Ownership

2.9M shares outstanding ยท as of May 6, 2026
8.1%10%+ / strategic
Ownership
10%+ / strategic8.13%233,219
Institutions4.48%128,584
Public float87.39%2,506,444

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 0

View all โ†’
Insider% of sharesShares
No insiders recorded yet.

Institutional holders 18

View all โ†’
HolderValue% of shares
Vanguard Group Inc$365.5K1.88%
DRW Securities, LLC$170.5K0.88%
Geode Capital Management, LLC$110.7K0.75%
LPL Financial LLC$88.1K0.45%
JPMorgan Chase & Co$50.9K0.26%
BlackRock, Inc.$23.9K0.12%
Morgan Stanley$7.3K0.04%
UBS Group AG$7.1K0.04%
Tower Research Capital LLC (TRC)$3.6K0.02%
Osaic Holdings, Inc.$3.4K0.02%

Activity

Mar 31, 2026View all โ†’
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ฮ”Position afterImpact
Q2 2026
as of
LPL Financial LLC
13F manager
ExitCommon stock$-88.1K-13K
-100.00%
0
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon stock$36.3K+7K
+48.86%
21,626
0.75% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
ExitCommon stock$-23.9K-4K
-100.00%
0
low
Q2 2026
as of
Curio Wealth, LLC
13F manager
ExitCommon stock$-7-1
-100.00%
0
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
The PNC Financial Services Group, Inc.Passive13Gโ€”233,219โ€”

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
โ€”โ€”โ€”127636207โ€”